[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2014003886A - Composiciones farmaceuticas de n-metil-2-[3-((e) 2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]benzamida. - Google Patents

Composiciones farmaceuticas de n-metil-2-[3-((e) 2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]benzamida.

Info

Publication number
MX2014003886A
MX2014003886A MX2014003886A MX2014003886A MX2014003886A MX 2014003886 A MX2014003886 A MX 2014003886A MX 2014003886 A MX2014003886 A MX 2014003886A MX 2014003886 A MX2014003886 A MX 2014003886A MX 2014003886 A MX2014003886 A MX 2014003886A
Authority
MX
Mexico
Prior art keywords
pyridin
indazol
benzamide
vinyl
methyl
Prior art date
Application number
MX2014003886A
Other languages
English (en)
Inventor
Daniel Scott Gierer
James Eric Morgado
Brendan John Murphy
Daryl Michael Simmons
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2014003886A publication Critical patent/MX2014003886A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que contienen axitinib, el cual es conocido como N-metil-2-[3-((E)-2-piridin-2-il-vinil)-1H-indazol-6-ilsulfanil]- benzamida o 6-[2-(metilcarbamoil)fenilsulfanil]-3-E-[2-(piridin-2- il)etenil]indazol, o formas cristalinas de los mismos, que protegen al axitinib de la degradación, incluyendo fotodegradación, así como el uso terapéutico de dichas composiciones; la presente invención se refiere también a fotodegradantes novedosos de axitinib.
MX2014003886A 2011-09-30 2012-09-26 Composiciones farmaceuticas de n-metil-2-[3-((e) 2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]benzamida. MX2014003886A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541525P 2011-09-30 2011-09-30
PCT/IB2012/055126 WO2013046133A1 (en) 2011-09-30 2012-09-26 Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide

Publications (1)

Publication Number Publication Date
MX2014003886A true MX2014003886A (es) 2014-05-13

Family

ID=47116146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003886A MX2014003886A (es) 2011-09-30 2012-09-26 Composiciones farmaceuticas de n-metil-2-[3-((e) 2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]benzamida.

Country Status (15)

Country Link
US (1) US20140248347A1 (es)
EP (1) EP2760434A1 (es)
JP (1) JP2013079234A (es)
KR (1) KR20140069297A (es)
CN (1) CN103826618A (es)
AR (1) AR088195A1 (es)
AU (1) AU2012313885A1 (es)
BR (1) BR112014007163A2 (es)
CA (1) CA2847860A1 (es)
IL (1) IL231437A0 (es)
MX (1) MX2014003886A (es)
RU (1) RU2014107767A (es)
SG (1) SG11201400145VA (es)
TW (2) TW201531309A (es)
WO (1) WO2013046133A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2518898C2 (ru) † 2007-04-05 2014-06-10 Пфайзер Продактс Инк. Кристаллические формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-(пиридин-2-ил)этенил]индазола, пригодные для лечения аномального роста клеток у млекопитаюших
US9205078B2 (en) 2011-11-11 2015-12-08 Pfizer Inc. N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
JP6612232B2 (ja) 2013-08-28 2019-11-27 クラウン バイオサイエンス インコーポレイテッド（タイカン） 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
ES2899457T3 (es) 2014-02-04 2022-03-11 Pfizer Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer
CN104013589A (zh) * 2014-05-07 2014-09-03 万特制药(海南)有限公司 一种阿西替尼口腔崩解片及其制备方法
EP3185866A1 (en) 2014-08-25 2017-07-05 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
CN105769785B (zh) * 2014-12-26 2019-02-01 四川科伦药物研究院有限公司 一种阿昔替尼片剂的制备方法
WO2016108106A1 (en) * 2014-12-29 2016-07-07 Shilpa Medicare Limited An improved process for preparation of axitinib
SG11201706918YA (en) 2015-02-26 2017-09-28 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
US10869924B2 (en) 2015-06-16 2020-12-22 Merck Patent Gmbh PD-L1 antagonist combination treatments
CN106913547B (zh) * 2015-12-28 2021-09-14 山东新时代药业有限公司 一种阿昔替尼片剂及其制备方法
MX2019003755A (es) 2016-10-06 2019-08-12 Pfizer Regimen de dosificacion de avelumab para el tratamiento de cancer.
CN106918658B (zh) * 2017-01-22 2020-01-31 合肥拓锐生物科技有限公司 一种阿昔替尼原料及其制剂中有关物质的分析方法
CN109928964B (zh) * 2017-12-18 2022-04-15 江苏开元药业有限公司 一种阿西替尼中间体的合成方法
WO2019234581A1 (en) * 2018-06-04 2019-12-12 Glenmark Pharmaceuticals Limited Pharmaceutical compositions of axitinib
WO2020003196A1 (en) * 2018-06-28 2020-01-02 Alembic Pharmaceuticals Limited Pharmaceutical composition of axitinib
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
WO2020225413A1 (en) 2019-05-09 2020-11-12 Synthon B.V. Pharmaceutical composition comprising axitinib
CN112999176B (zh) * 2019-12-19 2022-09-13 鲁南制药集团股份有限公司 一种阿昔替尼片剂
CN113943271B (zh) * 2020-07-15 2023-11-14 鲁南制药集团股份有限公司 一种阿昔替尼晶型及其制备方法
IL315265A (en) 2022-03-03 2024-10-01 Pfizer Multiple antibodies and their uses
EP4282415A1 (en) 2022-05-26 2023-11-29 Genepharm S.A. A stable tablet composition of axitinib

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
BRPI0409230A (pt) 2003-04-03 2006-03-28 Pfizer formas de dosagem compreendendo ag013736
MX2007005273A (es) 2004-11-02 2007-07-19 Pfizer Formas polimorficas de 6-[2-(metilcarbamoil)fenilsulfanil]-3- e-[2-(piridin-2-il)etenil]indazol.
WO2006048745A1 (en) 2004-11-02 2006-05-11 Pfizer Inc. Methods for preparing indazole compounds
WO2006048746A2 (en) 2004-11-02 2006-05-11 Pfizer Inc. Methods for the removal of heavy metals
CN101052633A (zh) 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
CA2586174A1 (en) 2004-11-02 2006-05-11 Brigitte Leigh Ewanicki Methods of preparing indazole compounds
EP1885338A1 (en) 2005-05-19 2008-02-13 Pfizer, Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
RU2518898C2 (ru) 2007-04-05 2014-06-10 Пфайзер Продактс Инк. Кристаллические формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-(пиридин-2-ил)этенил]индазола, пригодные для лечения аномального роста клеток у млекопитаюших

Also Published As

Publication number Publication date
RU2014107767A (ru) 2015-11-10
JP2013079234A (ja) 2013-05-02
BR112014007163A2 (pt) 2017-04-04
AR088195A1 (es) 2014-05-14
AU2012313885A1 (en) 2014-03-13
US20140248347A1 (en) 2014-09-04
KR20140069297A (ko) 2014-06-09
SG11201400145VA (en) 2014-03-28
TW201328725A (zh) 2013-07-16
IL231437A0 (en) 2014-04-30
EP2760434A1 (en) 2014-08-06
WO2013046133A1 (en) 2013-04-04
TW201531309A (zh) 2015-08-16
CA2847860A1 (en) 2013-04-04
CN103826618A (zh) 2014-05-28

Similar Documents

Publication Publication Date Title
MX2014003886A (es) Composiciones farmaceuticas de n-metil-2-[3-((e) 2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]benzamida.
MY165514A (en) Substituted 4-phenyl-pyridines for the treatment of nk-1 receptor related diseases
MD20140109A2 (ro) Compuşi ai indolului şi indazolului care activează AMPK
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
EA033343B1 (ru) Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
JO3459B1 (ar) تركيبات صيدلانية لعلاج مرض الزهايمر
MY151246A (en) Benzofuranyl derivatives
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
MX2016010777A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer.
PH12014502586A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2014012266A (es) Sintesis asimetricas para compuestos espiro-oxindol utiles como agentes terapeuticos.
PH12014502567A1 (en) Piperidine derivatives for gpr119 agonist
NZ746950A (en) Heterocyclic gpr119 agonist compounds
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
PH12015501223A1 (en) Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists
MX2014000855A (es) Moduladores receptores de glucagon de quinolinilo.
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors
GB2553685A8 (en) Novel éthynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis